Core Viewpoint - Bavarian Nordic A/S has initiated a share buy-back program with a total budget of DKK 500 million for 2026, starting with a first tranche of DKK 150 million aimed at adjusting the capital structure [1][2]. Group 1: Share Buy-Back Program Details - The share buy-back program is authorized by the annual general meeting held on April 9, 2025, and complies with EU regulations on market abuse [2]. - The program will be managed by Nordea, which has been appointed as the lead manager to execute the buy-back independently [3]. - The buy-back will commence on January 7, 2026, and is expected to be completed by February 13, 2026, with a maximum of 1,500,000 shares to be repurchased [7]. Group 2: Transaction Terms - The maximum aggregate purchase price for the first tranche is DKK 150 million, and the maximum number of shares that can be purchased on any single trading day is limited to 25% of the average daily trading volume over the preceding 20 trading days [7]. - Prior to the program, Bavarian Nordic held 966,845 treasury shares, which is 1.22% of the company's share capital [5].

Core Viewpoint - Bavarian Nordic A/S has established a long-term incentive program for Executive Management and selected employees, which includes performance restricted stock units (Performance RSUs) and a warrant program as part of its Remuneration Policy [1][8]. Group 1: Performance Restricted Stock Units (Performance RSUs) - A total of 104,009 Performance RSUs are granted to members of Executive Management, with the value equating to up to 100% of their fixed annual base wage at the date of grant [2]. - Each Performance RSU is valued at DKK 188.26, based on the average market price of the company's shares on Nasdaq Copenhagen over a 15-business-day period prior to the grant [3]. - The Performance RSUs will vest in three years, contingent upon meeting specific Key Performance Indicators (KPIs) set by the Board of Directors [2]. Group 2: Warrant Program - A total of 1,270,820 warrants are granted to selected employees, allowing them to subscribe for up to 1,270,820 shares at a nominal value of DKK 10 each [4]. - The subscription price for the warrants is set at DKK 216.50 per share, which is the average market price plus a 15% premium over a 15-business-day period prior to the grant [4]. - The value of each warrant is calculated at DKK 69.52 using the Black-Scholes model, based on a share price of DKK 188.00 and a risk-free interest rate of 2.0% [5].

Group 1 - Bavarian Nordic announced the appointment of Anne Louise Eberhard as the new chairperson of the board and Heidi Hunter as the new vice-chairperson [1] - Heidi Hunter has over 25 years of experience in the pharmaceutical industry, having held leadership positions at Cardinal Health, UCB, Boehringer Ingelheim, IQVIA, and Centocor, among others [2] - In addition to her role as vice-chairperson, Heidi Hunter is a member of the Nomination and Compensation Committee and the Science and Technology Committee [3] Group 2 - Bavarian Nordic is a global vaccine company focused on improving health and saving lives through innovative vaccines, including mpox and smallpox vaccines [4]

Core Viewpoint - Bavarian Nordic A/S has announced a one-time share buy-back program of up to DKK 500 million to be executed over the next 12 months, reflecting a strong cash position and positive cash flow from operations [1][2]. Financial Position - As of September 30, 2025, Bavarian Nordic reported securities, cash, and cash equivalents totaling DKK 2,978 million, with approximately DKK 800 million earmarked for deferred payments to GSK and related royalties and taxes [2]. - The company believes that the cash balance after the buy-back program will be sufficient to maintain operational flexibility in an uncertain environment [2]. Share Buy-back Program Details - The shares bought back will be held as treasury stock to adjust the company's capital structure [3]. - The program will be executed in accordance with the authorization from the general meeting of shareholders and will comply with safe harbour regulations [3]. - Further details regarding the key terms of the program will be provided following the Board of Directors' final decision to launch the program [3]. Treasury Shares - Currently, Bavarian Nordic holds 966,845 shares as treasury shares, which represents 1.22% of the company's share capital [4]. - A portion of these treasury shares will be utilized to meet the company's obligations related to long-term share-based incentive programs for the Board of Directors and Executive Management [4]. Company Overview - Bavarian Nordic is a global vaccine company focused on improving health and saving lives through innovative vaccines, including mpox and smallpox vaccines, and has a strong portfolio of travel vaccines [5].

Core Points - Bavarian Nordic A/S is hosting a shareholder meeting on December 11, 2025, to discuss the state of business and recap the company's strategy [1] - The meeting will take place at Tivoli Hotel & Congress Center in Copenhagen from 09:00 am to 10:30 am CET and will be conducted in English [1] - Shareholders must register in advance via the company's shareholder portal by December 9, 2025, due to limited seating [2] - Admission cards will be sent via email upon registration and must be presented at the meeting [3] - A recording of the meeting will be available on the company's website after the event [3] - Shareholders unable to attend can submit questions via email to be addressed during the meeting [3] Company Overview - Bavarian Nordic is a global vaccine company focused on improving health and saving lives through innovative vaccines [4] - The company is a preferred supplier of mpox and smallpox vaccines to governments, enhancing public health preparedness [4] - Bavarian Nordic also has a leading portfolio of travel vaccines [4]

Core Points - Bavarian Nordic A/S announced the immediate resignation of Chair of the Board, Luc Debruyne, with Vice Chair Anne Louise Eberhard appointed as the new Chair [1][2] - Luc Debruyne expressed gratitude for the company's achievements during his tenure and emphasized the need for the board to focus on the next phase of development [2] - Anne Louise Eberhard acknowledged Debruyne's contributions and highlighted the importance of stability and continuity in governance as the company continues its growth trajectory [3] Company Overview - Bavarian Nordic is a global vaccine company dedicated to improving health and saving lives through innovative vaccines, including mpox and smallpox vaccines [4]

Core Points - The voluntary takeover offer by Innosera ApS for Bavarian Nordic has been withdrawn due to insufficient acceptance rates, with only 60% of shareholders accepting the offer, falling short of the required 66.67% [2][3][4] - Bavarian Nordic will continue as an independent company, maintaining its current growth strategy and inviting shareholders to an information meeting to discuss business status and future plans [4][5] Company Overview - Bavarian Nordic is a global vaccine company focused on improving health through innovative vaccines, including being a preferred supplier of mpox and smallpox vaccines [7]

Core Insights - Bavarian Nordic A/S has received notification from Morgan Stanley regarding their shareholding, which stands at 5.20% of the shares and voting rights as of October 23, 2025 [1] Company Overview - Bavarian Nordic is a global vaccine company focused on improving health and saving lives through innovative vaccines [2] - The company is a preferred supplier of mpox and smallpox vaccines to governments, enhancing public health preparedness [2] - Bavarian Nordic also has a leading portfolio of travel vaccines [2]

Core Viewpoint - Innosera ApS has published a third supplement to its offer document, lowering the minimum acceptance condition for its takeover bid of Bavarian Nordic A/S from 75% to 66 2/3% of the voting rights and share capital [2][4]. Offer Details - The offer period has been extended, with the expiry time changed from 5:00 p.m. (CET) to 11:59 p.m. (CET) on November 5, 2025 [3]. - All other terms and conditions of the offer remain unchanged as per the previous supplements [4]. Shareholder Response - Institutional shareholders representing approximately 5.3% of Bavarian Nordic's share capital have committed to accept the improved offer during the extended period [5]. - As of October 21, 2025, the Offeror has received acceptances and binding commitments indicating a preliminary acceptance level of approximately 36.1% [5]. Regulatory Approval - The third supplement has been approved by the Danish Financial Supervisory Authority [6].

Core Viewpoint - Bavarian Nordic's Board of Directors maintains its recommendation for shareholders to accept the takeover offer from Innosera ApS, citing the offer as fair and attractive based on the company's fundamental value and historical share price levels [2][3]. Offer Details - The takeover offer is for all issued and outstanding shares of Bavarian Nordic, excluding treasury shares, made by Innosera ApS, which is controlled by Nordic Capital Fund XI and Permira Beteiligungsberatung GmbH [1]. - The offer period has been extended, and the offer price has been increased, prompting the Board to reiterate its recommendation [2][3]. Company Background - Bavarian Nordic is a global vaccine company focused on improving health through innovative vaccines, including mpox and smallpox vaccines, and has a strong portfolio of travel vaccines [7].